"The U.S. Food and Drug Administration and the U.S. Environmental Protection Agency today issued draft updated advice on fish consumption. The two agencies have concluded pregnant and breastfeeding women, those who might become pregnant, and young"...
Plasma-Lyte 56 and Dextrose
Plasma-Lyte 56 Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Plasma-Lyte 56 and 5% Dextrose Injection (multiple electrolytes and dextrose injection, type 1) is a fluid and electrolyte replenishment and caloric supply used as a source of water, electrolytes, and calories or as an alkalinizing agent. This medication is available in generic form. Common side effects include fever, injection site reactions (infection, blood clotting, swelling), or increase in blood volume.
Dosage of Plasma-Lyte 56 and 5% Dextrose is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. Plasma-Lyte 56 and 5% Dextrose may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Plasma-Lyte 56 and 5% Dextrose should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Plasma-Lyte 56 and 5% Dextrose Injection (multiple electrolytes and dextrose injection, type 1) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Plasma-Lyte 56 FDA Prescribing Information: Side Effects
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
Read the entire FDA prescribing information for Plasma-Lyte 56 (Multiple Electrolytes and Dextrose Injection in Viaflex Plastic Container)
Additional Plasma-Lyte 56 and Dextrose Information
Report Problems to the Food and Drug Administration
Weight Loss Wisdom
Get tips, recipes and inspiration.